Orbimed Advisors LLC Prelude Therapeutics Inc Call Options Transaction History
Orbimed Advisors LLC
- $4.24 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PRLD
# of Institutions
71Shares Held
35.7MCall Options Held
500Put Options Held
300-
Baker Bros. Advisors LP New York, NY10.1MShares$12 Million0.22% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.77MShares$4.48 Million0.14% of portfolio
-
Boxer Capital, LLC San Diego, CA1.71MShares$2.03 Million0.19% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.1MShares$1.31 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.07MShares$1.27 Million0.0% of portfolio
About Prelude Therapeutics Inc
- Ticker PRLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,369,200
- Market Cap $43.3M
- Description
- Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...